阿托帕沙
阿托帕沙 性质
| 沸点 | 671.0±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.22 |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：250 mg/mL（473.82 mM；需要超声波） |
| 酸度系数(pKa) | 7.43±0.20(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| InChIKey | QWKAUGRRIXBIPO-UHFFFAOYSA-N |
| SMILES | C(=O)(C1=CC(N2CCOCC2)=C(OC)C(C(C)(C)C)=C1)CN1CC2=C(C1=N)C(F)=C(OCC)C(OCC)=C2 |
阿托帕沙 用途与合成方法
PAR-1
Atopaxar inhibits haTRAP (high-affinity thrombin receptor activating peptide) binding to PAR-1 on human platelet membranes in a concentration-dependent manner, with an IC
50
of 0.019 μM.
Atopaxar inhibits human platelet aggregation induced by thrombin or TRAP in a concentration-dependent manner.
Atopaxar does not inhibit PRP (platelet-rich plasma) aggregation induced by ADP, U46619, collagen, and PAR-4ap, up to a concentration of 20 μM.
Atopaxar (30-100 mg/kg; p.o.) causes a dose-dependent prolongation of the time to occlusion of the femoral artery in photochemically-induced thrombosis (PIT) guinea pigs model.
Atopaxar does not prolong bleeding time in guinea pigs at the highest tested dosage of 1000 mg/kg.
| Animal Model: | Guinea pigs, PIT model |
| Dosage: | Oral administration |
| Administration: | 10 mg/kg, 30 mg/kg, 100 mg/kg |
| Result: | Prolonged the time to occlusion by 1.8-fold and 2.4-fold at 30 mg/kg and 100 mg/kg, respectively, compared with controls. |
阿托帕沙 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-18200 | 阿托帕沙 | 751475-53-3 | 1 mg | 675 |
| 2026-09-15 | HY-18200 | 2-(5,6-二乙氧基-7-氟-1,3-二氢-1-亚氨基-2H-异吲哚-2-基)-1-[3-叔丁基-4-甲氧基-5-(4-吗啉基)苯基]乙酮 | 751475-53-3 | 5mg | 2200 |
